Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.36 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7973269 | 0.94 | ZDHHC7 (0.69) | ZDHHC7CA1CA2LCKPPARD | |
| SCHEMBL16860506 | 0.92 | ZDHHC7 (0.72) | ZDHHC7CA1CA2LCKPPARD | |
| SCHEMBL1415798 | 0.89 | ZDHHC7 (0.80) | ZDHHC7CA1CA2LCKPPARD | |
| SCHEMBL13248927 | 0.89 | ZDHHC7 (0.73) | ZDHHC7CA1CA2LCKPPARD | |
| SCHEMBL13069761 | 0.89 | ZDHHC7 (0.73) | ZDHHC7CA1CA2LCKPPARD | |
| SCHEMBL719382 | 0.89 | ZDHHC7 (0.73) | ZDHHC7CA1CA2LCKPPARD | |
| SCHEMBL23795547 | 0.86 | — | — | |
| SCHEMBL27837692 | 0.86 | ZDHHC7 (0.84) | ZDHHC7CA1CA2LCKPPARD | |
| SCHEMBL1107132 | 0.86 | — | — | |
| SCHEMBL1415237 | 0.84 | ZDHHC7 (0.65) | ZDHHC7CA1CA2LCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089638-A1 | DITHIOCARBAMATE STAPLED PEPTIDES AND METHODS OF MAKING AND USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE | 2022-03-24 | — | — | US | claimed |
| CN-111909077-A | 2- (1-bromocyclobutyl) pyridine and synthesis method thereof | 南通大学 | 2020-11-10 | — | — | CN | claimed |
| US-20260132172-A1 | IN VITRO BIOSYNTHESIS OF DIVERSE PYRIDINE-BASED MACROCYCLIC PEPTIDES | The Brd. of Trustees of the Univ. of Illinois (US) | 2026-05-14 | — | — | US | disclosed |
| CN-114008065-B | Glycyrrhetinic acid derivatives for the treatment of hyperkalemia | 阿德利克斯股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2025006976-A2 | MRNA DISPLAY LIBRARIES AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-5474988-A | Analgesics, antiinflammatory agents | KALI-CHEMIE PHARMA GMBH (DE) | 1995-12-12 | — | — | US | disclosed |
| EP-0521496-B1 | Process for producing optically active carboxylic acids | CONSORTIUM ELEKTROCHEM IND (DE) | 1994-10-19 | — | — | EP | disclosed |
| EP-0614899-A1 | 5-Phenyl-pyrrolo-1,4-benzoxazine and thiazine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | Kali-Chemie Pharma GmbH (DE) | 1994-09-14 | — | — | EP | disclosed |
| US-5334730-A | Amidation with an 2-aminocarboxylic acid ester, cleavage the amide bond, solvent extraction to isolate | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1994-08-02 | — | — | US | disclosed |
| EP-0521496-A2 | Process for producing optically active carboxylic acids | Consortium für elektrochemische Industrie GmbH (DE) | 1993-01-07 | — | — | EP | disclosed |
| US-4789675-A | HYPOTENSIVE, ANTIISCHEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-12-06 | — | — | US | disclosed |
| EP-0233728-A1 | 1,4-Benzoxazine derivatives their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-08-26 | — | — | EP | disclosed |
| US-4640916-A | HYPOTENSION, ANTIISCHEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-02-03 | — | — | US | disclosed |
| EP-0186310-A1 | 1,4-Benzothiazine Derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132172-A1 | IN VITRO BIOSYNTHESIS OF DIVERSE PYRIDINE-BASED MACROCYCLIC PEPTIDES | MLX, PDHX, DLD | ZDHHC7 557/4885CA1 4344/4885CA2 4710/4885 |
| US-20220089638-A1 | DITHIOCARBAMATE STAPLED PEPTIDES AND METHODS OF MAKING AND USE THEREOF | TP53, TP53BP1, DNASE1L3 | ZDHHC7 2415/4885CA1 57/4885CA2 1713/4885 |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | ZDHHC7 3068/4885CA1 483/4885CA2 58/4885 |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | HSD11B2, HSD11B1, NR3C2 | ZDHHC7 2783/4885CA1 414/4885CA2 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.